Literature DB >> 35005078

A Cautionary Note: Botulinum Toxin for Cervical Dystonia Reconstituted in Sterile Water: More Pain, Still Gain.

Bart E K S Swinnen1, Stephanie C Golsteijn1, Anne-Fleur van Rootselaar1, Johannes H T M Koelman1.   

Abstract

Entities:  

Keywords:  botulinum toxin; injection site pain; sterile water

Year:  2021        PMID: 35005078      PMCID: PMC8721831          DOI: 10.1002/mdc3.13356

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


× No keyword cloud information.
Intramuscular injection with botulinum toxin is an evidence‐based treatment for cervical dystonia. The injection is evidently accompanied by a certain degree of local injection site pain, but is generally well tolerated. We report four cervical dystonia cases who were inadvertently injected with botulinum toxin type A (Dysport®) reconstituted in sterile water instead of isotonic saline. All patients reported intense injection site pain at the moment of injection, perceived as much more intense than previous injections (Table 1). No other symptoms were reported. The pain improved rapidly over a couple of minutes but persisted to a lesser degree for 2 hours to 2 days. Effectivity of the botulinum toxin treatment was comparable to previous injections in all patients regarding effect latency, effect duration and symptom improvement as measured on a visual analogue scale.
TABLE 1

Characteristics of patients injected with botulinum toxin (Dysport®) reconstituted in sterile water

Subject 1Subject 2Subject 3Subject 4
SexMMFF
Age (yr)73445967
Botulinum treatment
Duration (yr)2119512
Dose (IU)460260120540
Tsui score
Saline*10.82.8610.3
Sterile water124712
Effect latency
Saline* (w)1.51.41.61.5
Sterile water (w)21.51 1 day
Effect duration
Saline* (w)8.78.27.67.3
Sterile water (w)77.588
Dystonia improvement (VAS)
Saline*3.11.113.5
Sterile water3336
Injection site pain
IntensityModerateModerateModerateSevere†
Duration2 days1 day2 hr1 day

Following parameters are described for four patients; sex, age, duration of treatment with botulinum toxin, current botulinum toxin dose, Tsui score at time of next treatment (ie, approximately 3 months after injection), latency to onset of effect on dystonia, duration of effect on dystonia, extent of dystonia improvement (the latter three parameters were obtained retrospectively at the next injection session approximately 3 months later), intensity and duration of injection site pain.

Abbreviations: yr, years; IU, international units; w, weeks; VAS, visual analogue scale; S, saline; W, sterile water; *, mean of previous 10 injections; †, leading to presyncope.

Characteristics of patients injected with botulinum toxin (Dysport®) reconstituted in sterile water Following parameters are described for four patients; sex, age, duration of treatment with botulinum toxin, current botulinum toxin dose, Tsui score at time of next treatment (ie, approximately 3 months after injection), latency to onset of effect on dystonia, duration of effect on dystonia, extent of dystonia improvement (the latter three parameters were obtained retrospectively at the next injection session approximately 3 months later), intensity and duration of injection site pain. Abbreviations: yr, years; IU, international units; w, weeks; VAS, visual analogue scale; S, saline; W, sterile water; *, mean of previous 10 injections; †, leading to presyncope. These cases highlight the importance of proper reconstitution of botulinum toxin (ie, in preservative‐free sterile saline 0.9%), as dissolution in sterile water generates intense injection site pain. To our knowledge, this finding has not as such been reported before. However, it is in line with a recent proposed model to investigate pain, that is, intramuscular injection of sterile water or hypertonic saline. Clinicians are probably unaware of this association, as a survey amongst dermatological surgeons revealed 3.5% of them to reconstitute botulinum toxin in sterile water. Next to safeguarding proper reconstitution, several other measures have been reported to decrease injection site pain including precooling with ice, topical lidocaine administration, injection needles with smaller diameter, as well as dilution in lidocaine, preservative‐containing saline or pH‐normalized solutions. Mechanistically, the injection of a hypotonic fluid generates a sudden osmotic gradient in the muscle tissue leading to a seriously disturbed cellular osmotic homeostasis and hence pain. Botulinum toxin itself is probably not involved in additional pain generation, as injection of pure saline is as painful as botulinum toxin type A dissolved in saline. Despite the adverse effect of increased injection site pain, these cases indicate that the clinical effectivity of botulinum toxin is probably not affected by dissolution in sterile water instead of saline. As sodium chloride has been reported to facilitate dissociation of free neurotoxin, a certain impact on the pharmacological potency of botulinum toxin can however not be excluded. Yet, this potential impact does not seem to be of clinical importance. This finding might be helpful in counseling future patients in the event of improper reconstitution. To conclude, cervical dystonia treatment with intramuscular injection of botulinum toxin reconstituted in sterile water instead of saline is probably equally effective but is associated with transient intense injection site pain.

Author Roles

(1) Patient care; (2) Manuscript preparation: A. Writing of the first draft, B. Review and critique. B.E.K.S.S.: 1, 2A S.C.C.: 1, 2B A.F.R.: 1, 2B J.H.T.M.K.: 1, 2B

Disclosures

Ethical Compliance Statement

Written informed consent has been obtained from all patients. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Ethical standards as laid down in the 1964 Declaration of Helsinki Ethical guidelines have been followed.

Funding Sources and Conflicts of Interest

Dr Koelman reports grants from Ipsen, Allergan, Merz. The other authors declare no conflict of interest.

Financial Disclosures for the Previous 12 Months

The authors declare that there are no additional disclosures to report.
  5 in total

1.  Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.

Authors:  Gottfried Kranz; Thomas Sycha; Bernhard Voller; Andreas Gleiss; Peter Schnider; Eduard Auff
Journal:  Dermatol Surg       Date:  2006-07       Impact factor: 3.398

2.  Recommendations and current practices for the reconstitution and storage of botulinum toxin type A.

Authors:  Austin Liu; Alastair Carruthers; Joel L Cohen; William P Coleman; Jeffrey S Dover; C William Hanke; Ronald L Moy; David M Ozog
Journal:  J Am Acad Dermatol       Date:  2011-11-04       Impact factor: 11.527

3.  Double-blind study of botulinum toxin in spasmodic torticollis.

Authors:  J K Tsui; A Eisen; A J Stoessl; S Calne; D B Calne
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

4.  Sterile water; a novel and promising human experimental craniofacial muscle pain model.

Authors:  Sofia Louca Jounger; Johanna Svedenlöf; Reija Elenius; Christoffer Källkrans; Emil Scheid; Malin Ernberg; Nikolaos Christidis
Journal:  J Oral Rehabil       Date:  2021-02-02       Impact factor: 3.837

5.  Studies on the dissociation of botulinum neurotoxin type A complexes.

Authors:  Karl-Heinz Eisele; Klaus Fink; Martin Vey; Harold V Taylor
Journal:  Toxicon       Date:  2010-12-30       Impact factor: 3.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.